Given the enormity of the deal between CME and CBoT it is not surprising that a number of questions and issues have arisen. It would appear that in their haste to get the deal signed and delivered to their respective shareholders, the boards of both exchanges may have overlooked a number of unanswered questions which have an impact if not on the Chicago futures arena itself, then at least on the broader listed derivatives markets.
Here are some, but by no means all, of those questions:
To begin with, will the lack of an equities arm be a 'pro' or a 'con' for the combined exchange? Having both derivatives and equities seems to be a lot of hassle in Europe...